SCHEMBL22907219

SCHEMBL22907219

COC(CC1CCN(c2ncc(Br)cc2C#N)CC1)OC

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 17/20 0.43
JAK2 O60674 1/20 0.38
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CASP1 P29466 2/20 0.36
CASP7 P55210 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
USP2 O75604 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27098732 0.84 KDM4E (0.37) OPRK1KDM4EMEN1ALDH1A1CASP1
SCHEMBL22907440 0.82 OPRK1 (0.45) OPRK1
SCHEMBL22996455 0.74 CNR2 (0.50) OPRK1KDM4EMEN1ALDH1A1CASP1
SCHEMBL27098865 0.73 PDE10A (0.46) OPRK1KMT2AMAPT
SCHEMBL19343217 0.73 CNR2 (0.52) OPRK1KDM4EMEN1ALDH1A1CASP1
SCHEMBL15971696 0.73 OPRK1 (0.45) OPRK1JAK2
SCHEMBL17387847 0.73 OPRK1 (0.45) OPRK1JAK2
SCHEMBL22907220 0.73 MAPT (0.39) MAPT
SCHEMBL22031993 0.72 OPRK1 (0.49) OPRK1JAK2KDM4EMEN1ALDH1A1
SCHEMBL25065698 0.72 OPRK1 (0.49) OPRK1JAK2KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN OPRK1 3675/4885JAK2 2782/4885KDM4E 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.